These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22030098)

  • 1. Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation.
    Behrend AM; Harding CO; Shoemaker JD; Matern D; Sahn DJ; Elliot DL; Gillingham MB
    Mol Genet Metab; 2012 Jan; 105(1):110-5. PubMed ID: 22030098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
    Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
    J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD-/-) mouse to compensate a defective fatty acid β-oxidation.
    Tucci S; Herebian D; Sturm M; Seibt A; Spiekerkoetter U
    PLoS One; 2012; 7(9):e45429. PubMed ID: 23024820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
    Gillingham MB; Heitner SB; Martin J; Rose S; Goldstein A; El-Gharbawy AH; Deward S; Lasarev MR; Pollaro J; DeLany JP; Burchill LJ; Goodpaster B; Shoemaker J; Matern D; Harding CO; Vockley J
    J Inherit Metab Dis; 2017 Nov; 40(6):831-843. PubMed ID: 28871440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
    Ørngreen MC; Madsen KL; Preisler N; Andersen G; Vissing J; Laforêt P
    Neurology; 2014 Feb; 82(7):607-13. PubMed ID: 24453079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-chain fatty acid oxidation during early human development.
    Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
    Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study.
    Karunanidhi A; Van't Land C; Rajasundaram D; Grings M; Vockley J; Mohsen AW
    J Inherit Metab Dis; 2022 May; 45(3):541-556. PubMed ID: 35076099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very long-chain acyl-CoA dehydrogenase (VLCAD-) deficiency-studies on treatment effects and long-term outcomes in mouse models.
    Tucci S
    J Inherit Metab Dis; 2017 May; 40(3):317-323. PubMed ID: 28247148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency.
    Gillingham MB; Scott B; Elliott D; Harding CO
    Mol Genet Metab; 2006; 89(1-2):58-63. PubMed ID: 16876451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional ketosis improves exercise metabolism in patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Bleeker JC; Visser G; Clarke K; Ferdinandusse S; de Haan FH; Houtkooper RH; IJlst L; Kok IL; Langeveld M; van der Pol WL; de Sain-van der Velden MGM; Sibeijn-Kuiper A; Takken T; Wanders RJA; van Weeghel M; Wijburg FA; van der Woude LH; Wüst RCI; Cox PJ; Jeneson JAL
    J Inherit Metab Dis; 2020 Jul; 43(4):787-799. PubMed ID: 31955429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food withdrawal lowers energy expenditure and induces inactivity in long-chain fatty acid oxidation-deficient mouse models.
    Diekman EF; van Weeghel M; Wanders RJ; Visser G; Houten SM
    FASEB J; 2014 Jul; 28(7):2891-900. PubMed ID: 24648546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation.
    McCoin CS; Piccolo BD; Knotts TA; Matern D; Vockley J; Gillingham MB; Adams SH
    J Inherit Metab Dis; 2016 May; 39(3):399-408. PubMed ID: 26907176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
    Tucci S; Behringer S; Spiekerkoetter U
    FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A heterozygous missense mutation in adolescent-onset very long-chain acyl-CoA dehydrogenase deficiency with exercise-induced rhabdomyolysis.
    Hisahara S; Matsushita T; Furuyama H; Tajima G; Shigematsu Y; Imai T; Shimohama S
    Tohoku J Exp Med; 2015 Apr; 235(4):305-10. PubMed ID: 25843429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-exercise medium-chain triglyceride application prevents acylcarnitine accumulation in skeletal muscle from very-long-chain acyl-CoA-dehydrogenase-deficient mice.
    Primassin S; Tucci S; Herebian D; Seibt A; Hoffmann L; ter Veld F; Spiekerkoetter U
    J Inherit Metab Dis; 2010 Jun; 33(3):237-46. PubMed ID: 20446112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial.
    Storgaard JH; Løkken N; Madsen KL; Voermans NC; Laforêt P; Nadaj-Pakleza A; Tard C; van Hall G; Vissing J; Ørngreen MC
    J Inherit Metab Dis; 2022 May; 45(3):517-528. PubMed ID: 35066899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
    Yamada K; Taketani T
    J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and pathomechanisms of cardiomyopathy in very long-chain acyl-CoA dehydrogenase deficient (VLCAD(-/-)) mice.
    Tucci S; Flögel U; Hermann S; Sturm M; Schäfers M; Spiekerkoetter U
    Biochim Biophys Acta; 2014 May; 1842(5):677-85. PubMed ID: 24530811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder.
    Gillingham MB; Harding CO; Schoeller DA; Matern D; Purnell JQ
    Am J Physiol Endocrinol Metab; 2013 Nov; 305(10):E1299-308. PubMed ID: 24064340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Metabolic Defects in Fatty Acid Oxidation Using Peripheral Blood Mononuclear Cells Loaded with Deuterium-Labeled Fatty Acids.
    Yuasa M; Hata I; Sugihara K; Isozaki Y; Ohshima Y; Hara K; Tajima G; Shigematsu Y
    Dis Markers; 2019; 2019():2984747. PubMed ID: 30881520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.